Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.58 USD | -0.28% | -5.04% | -39.53% |
04-04 | Morgan Stanley Initiates Coverage on Mural Oncology With Overweight Rating, $13 Price Target | MT |
01-08 | Mural Oncology plc Announces Enhancements to Late-Stage Clinical Trials | CI |
EBIT - Change in analysts' estimates
Cash or Net Debt - Change in analysts' estimates
EBIT
Cash or Net Debt
- Stock Market
- Equities
- MURA Stock
- Revisions Mural Oncology plc